

# 抗癌藥物治療指引

## 胰臟癌

### 討論日期

團隊制訂：2019/12/31

核備日期：2020/3/31

## 《胰臟癌抗癌藥物治療指引》

### Neoadjuvant Chemotherapy

#### FOLFIRINOX

| 藥品名         | 劑量 mg/m <sup>2</sup> | 給藥日 | 頻率  | 週期 | 參考文獻 |
|-------------|----------------------|-----|-----|----|------|
| Irinotecan  | 180                  | 1   | Q2W | 4  | 1    |
| Oxaliplatin | 85                   | 1   | Q2W | 4  |      |
| Leucovorin  | 400                  | 1   | Q2W | 4  |      |
| 5-FU        | 400                  | 1   | Q2W | 4  |      |
| 5-FU        | 1200                 | 1-2 | Q2W | 4  |      |

#### modified FOLFIRINOX

| 藥品名         | 劑量 mg/m <sup>2</sup> | 給藥日 | 頻率  | 週期 | 參考文獻 |
|-------------|----------------------|-----|-----|----|------|
| Irinotecan  | 150*                 | 1   | Q2W | 4  | 2    |
| Oxaliplatin | 85                   | 1   | Q2W | 4  |      |
| Leucovorin  | 400                  | 1   | Q2W | 4  |      |
| 5-FU        | 1200                 | 1-2 | Q2W | 4  |      |

\*團隊共識

#### Gemcitabine + nab Paclitaxel

| 藥品名            | 劑量 mg/m <sup>2</sup> | 給藥日      | 頻率  | 週期  | 參考文獻 |
|----------------|----------------------|----------|-----|-----|------|
| Gemcitabine    | 1000                 | 1, 8, 15 | Q4W | 2-4 | 3    |
| nab-Paclitaxel | 125                  | 1, 8, 15 | Q4W | 2-4 |      |

### Only for known BRCA 1/2 or PALB2 mutation

#### Gemcitabine + Cisplatin

| 藥品名         | 劑量 mg/m <sup>2</sup> | 給藥日   | 頻率  | 週期  | 參考文獻 |
|-------------|----------------------|-------|-----|-----|------|
| Gemcitabine | 1000                 | 1, 15 | Q4W | 2-6 | 4    |
| Cisplatin   | 50                   | 1, 15 | Q4W | 2-6 |      |

### Adjuvant Chemotherapy

#### Preferred regimen

#### modified FOLFIRINOX

| 藥品名         | 劑量 mg/m <sup>2</sup> | 給藥日 | 頻率  | 週期 | 參考文獻 |
|-------------|----------------------|-----|-----|----|------|
| Irinotecan  | 150                  | 1   | Q2W | 12 | 5    |
| Oxaliplatin | 85                   | 1   | Q2W | 12 |      |
| Leucovorin  | 400                  | 1   | Q2W | 12 |      |
| 5-FU        | 1200                 | 1-2 | Q2W | 12 |      |

**Gemcitabine + Capecitabine**

| 藥品名          | 劑量 mg/m <sup>2</sup>    | 給藥日     | 頻率  | 週期 | 參考文獻 |
|--------------|-------------------------|---------|-----|----|------|
| Gemcitabine  | 1000                    | 1, 8, 5 | Q4W | 6  | 6    |
| Capecitabine | 1660 (750-1000)* PO BID | 1-21    | Q4W | 6  |      |

\*團隊共識

**Other Recommended Regimen****Gemcitabine**

| 藥品名         | 劑量 mg/m <sup>2</sup> | 給藥日      | 頻率  | 週期 | 參考文獻 |
|-------------|----------------------|----------|-----|----|------|
| Gemcitabine | 1000                 | 1, 8, 15 | Q4W | 6  | 6    |

**5 Fu + Leucovorin**

| 藥品名*       | 劑量 mg/m <sup>2</sup> | 給藥日 | 頻率  | 週期 | 參考文獻 |
|------------|----------------------|-----|-----|----|------|
| Leucovorin | 20                   | 1-5 | Q4W | 6  | 7    |
| 5-FU       | 425                  | 1-5 | Q4W | 6  |      |

## Locally Advanced or Metastatic Disease

### First line therapy

#### Good PS

#### Preferred regimen

##### FOLFIRINOX

| 藥品名         | 劑量 mg/m <sup>2</sup> | 給藥日 | 頻率  | 週期 | 參考文獻 |
|-------------|----------------------|-----|-----|----|------|
| Irinotecan  | 180                  | 1   | Q2W | 12 | 8    |
| Oxaliplatin | 85                   | 1   | Q2W | 12 |      |
| Leucovorin  | 400                  | 1   | Q2W | 12 |      |
| 5-FU        | 400                  | 1   | Q2W | 12 |      |
| 5-FU        | 1200                 | 1-2 | Q2W | 12 |      |

##### modified FOLFIRINOX

| 藥品名         | 劑量 mg/m <sup>2</sup> | 給藥日 | 頻率  | 週期  | 參考文獻 |
|-------------|----------------------|-----|-----|-----|------|
| Irinotecan  | 150*                 | 1   | Q2W | 2-8 | 8    |
| Oxaliplatin | 85                   | 1   | Q2W | 2-8 |      |
| Leucovorin  | 400                  | 1   | Q2W | 2-8 |      |
| 5-FU        | 1200                 | 1-2 | Q2W | 2-8 |      |
|             |                      |     |     |     |      |

\*團隊共識

##### Gemcitabine + Nab Paclitaxel

| 藥品名            | 劑量 mg/m <sup>2</sup> | 給藥日      | 頻率  | 週期 | 參考文獻 |
|----------------|----------------------|----------|-----|----|------|
| Gemcitabine    | 1000                 | 1, 8, 15 | Q4W |    | 9    |
| Nab-Paclitaxel | 125                  | 1, 8, 15 | Q4W |    |      |

### Only for known BRCA 1/2 or PALB2 mutation

##### Gemcitabine + Cisplatin

| 藥品名*                      | 劑量 mg/m <sup>2</sup> | 給藥日   | 頻率  | 週期 | 參考文獻 |
|---------------------------|----------------------|-------|-----|----|------|
| Gemcitabine               | 1000                 | 1, 15 | Q4W |    | 4    |
| Cisplatin                 | 50                   | 1, 15 | Q4W |    |      |
| Followed by<br>± Olaparib | 300 mg PO BID        |       |     |    | 16   |

### Other Recommended Regimen

##### Gemcitabine + Erlotinib

| 藥品名*        | 劑量 mg/m <sup>2</sup> | 給藥日      | 頻率  | 週期 | 參考文獻 |
|-------------|----------------------|----------|-----|----|------|
| Gemcitabine | 1000                 | 1, 8, 15 | Q4W |    | 10   |
| Erlotinib   | 100                  | 1-28     | Q4W |    |      |

### Gemcitabine

| 藥品名*        | 劑量 mg/m <sup>2</sup> | 給藥日      | 頻率  | 週期 | 參考文獻 |
|-------------|----------------------|----------|-----|----|------|
| Gemcitabine | 1000                 | 1, 8, 15 | Q4W |    | 11   |

### Not list in NCCN

#### GOLF

| 藥品名*        | 劑量 mg/m <sup>2</sup> | 給藥日 | 頻率  | 週期 | 參考文獻 |
|-------------|----------------------|-----|-----|----|------|
| Gemcitabine | 1000                 | 1   | Q2W |    | 15   |
| Oxaliplatin | 85                   | 1   | Q2W |    |      |
| Leucovorin  | 120                  | 1   | Q2W |    |      |
| 5-FU        | 1200                 | 1-2 | Q2W |    |      |

#### TS-1

| 藥品名* | 劑量 mg/m <sup>2</sup> | 給藥日         | 頻率        | 週期 | 參考文獻 |
|------|----------------------|-------------|-----------|----|------|
| TS-1 | 80-120 PO            | 1-28 (1-14) | Q6W (Q3W) |    | 12   |

### Poor PS

#### Preferred regimen

### Gemcitabine

| 藥品名*        | 劑量 mg/m <sup>2</sup> | 給藥日      | 頻率  | 週期 | 參考文獻 |
|-------------|----------------------|----------|-----|----|------|
| Gemcitabine | 1000                 | 1, 8, 15 | Q4W |    | 11   |

#### Fix-dose-rate Gemcitabine

| 藥品名*        | 劑量 mg/m <sup>2</sup> | 給藥日      | 頻率  | 週期 | 參考文獻 |
|-------------|----------------------|----------|-----|----|------|
| Gemcitabine | 1000*                | 1, 8, 15 | Q4W |    | 13   |

\*Flow rate: 10mg/m<sup>2</sup>/min

### Metastatic, useful in certain circumstances

#### Pembrolizumab

| 藥品名*          | 劑量 mg/m <sup>2</sup> | 給藥日 | 頻率  | 週期 | 參考文獻 |
|---------------|----------------------|-----|-----|----|------|
| Pembrolizumab | 200 mg               | 1   | Q3W |    | 14   |

## 參考文獻

1. Murphy JE, Wo JY, Ryan DP, et al. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial. *JAMA Oncol.* 2018; 4:963-969.
2. Nanda RH, El-Rayes B, Maithel SK, et al. Neoadjuvant modified FOLFIRINOX and chemoradiation therapy for locally advanced pancreatic cancer improves resectability. *J Surg Oncol.* 2015;111:1028-34.
3. Miyashita T, Tajima H, Makino I, et al. Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-paclitaxel Reduces the Number of Cancer-associated Fibroblasts Through Depletion of Pancreatic Stroma. *Anticancer Res.* 2018; 38:337-343.
4. Oliver GR, Sugar E, Laheru D, et al. Family history of cancer and sensitivity to platinum chemotherapy in pancreatic adenocarcinoma. 2010 Gastrointestinal Cancers Symposium. Abstract No. 151.
5. Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. *N Engl J Med* 2018;379:2395-2406.
6. Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. *Lancet.* 2017;389:1011-1024.
7. Neoptolemos JP, Moore MJ, Cox TF, et al. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. *JAMA.* 2012;308:147-56.
8. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. *N Engl J Med* 2011;364:1817-25.
9. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. *N Engl J Med* 2013;369:1691-703.
10. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. *J Clin Oncol.* 2007;25:1960-6.
11. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. *J Clin Oncol.* 1997;15:2403-13.
12. Ueno H, Ioka T, Ikeda M, et al. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. *J Clin Oncol.* 2013;31:1640-8.
13. Gelibter A, Malaguti P, Di Cosimo S, et al. Fixed dose-rate gemcitabine infusion as first-line treatment for advanced-stage carcinoma of the pancreas and biliary tree. *Cancer.*

2005;104:1237-45.

14. Marabelle A, Le DT, Ascierto PA, et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. *J Clin Oncol.* 2020;38:1-10.
15. Gill S, Ko YJ, Cripps C, et al. PANCREOX: a randomized phase III study of 5-fluorouracil/leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy. *J Clin Oncol.* 2016; 34: 3914–3920.
16. Golan T, Hammel P, Reni M, et al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. *N Engl J Med.* 2019;381:317-327.